Clinical Trials Logo

Filter by:
NCT ID: NCT02492438 Completed - Clinical trials for Chronic Kidney Failure

13 Valent Pneumococcal Conjugate Vaccine in Chronic Dialysis Patients

Start date: February 2013
Phase: Phase 4
Study type: Interventional

To assess the immunogenicity of the PCV13 (13 valent pneumococcal conjugated vaccine) vaccine as compared to the PPV23 (23 valent pneumococcal polysaccharide vaccine) vaccine in patients treated with chronic hemodialysis that are pre-immunized with the PPSV23 vaccine or are PPV23 vaccine naïve by measuring the ELISA and OPA (opsonophagocytic assay) titers after 4 and 52 weeks.

NCT ID: NCT02491892 Completed - Breast Cancer Clinical Trials

A Study of Pertuzumab in Participants With Metastatic Breast Cancer

Start date: February 2003
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of pertuzumab (rhuMAb 2C4) in participants with metastatic breast cancer which has progressed during or after standard chemotherapy and which is not amenable to curative therapy. Those who are maintaining a response to therapy or who have stable disease at the end of the formal study period will continue treatment until disease progression or unacceptable toxicity. Approximately 120 participants will be enrolled.

NCT ID: NCT02491437 Completed - Female Infertility Clinical Trials

A Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Crinone 8% Intravaginal Progesterone Gel 90 mg Daily for Luteal Support in In-Vitro Fertilization (LOTUS II)

LOTUS II
Start date: July 2015
Phase: Phase 3
Study type: Interventional

The purpose of this randomized, two-arm and open label study is to demonstrate that the treatment of a daily dose of 3x10mg dydrogesterone orally is as effective and safe as the daily dose Crinone 8% intravaginal progesterone gel 90 mg for the luteal support in women who are unable to conceive a child and are undergoing IVF. The treatment will start on the day of oocyte retrieval and continue until pregnancy is negative or until week 12 gestation. Patients will be followed during treatment until 30 days after delivery to record any safety and tolerability data of the patient and their newborn (s).

NCT ID: NCT02490800 Completed - Neoplasms Clinical Trials

Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma

Start date: June 23, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

First in human, open-label, sequential dose escalation and expansion study of oral BAL101553 in adult patients with advanced solid tumors and adult patients with recurrent or progressive glioblastoma or high-grade glioma.

NCT ID: NCT02490618 Completed - Periodontitis Clinical Trials

The Use of a Probiotic Lozenge in the Treatment of Residual Pockets After Classical Non-surgical Therapy

Start date: January 2016
Phase: N/A
Study type: Interventional

The aim of this study is to determine the efficacy of the usage of a probiobitc lozenge in patients with residual bleeding pockets of ≥ 5mm 3 months following scaling and rootplaning. Simultaneously the additional benefit of subgingival application of probiotics via oil drops will be investigated.

NCT ID: NCT02489292 Completed - Clinical trials for Urea Cycle Disorders

Study to Evaluate the Efficacy of HepaStem in Urea Cycle Disorders Paediatric Patients (HEP002)

Start date: October 2014
Phase: Phase 2
Study type: Interventional

The aim of the study is to assess the efficacy of HepaStem treatment in paediatric patients suffering from urea cycle disorders.

NCT ID: NCT02489162 Completed - Facial Nerve Palsy Clinical Trials

The Role of a Device to Evaluate the Neuromuscular Function in Assessing Muscle in Facial Paralysis Patients

MyotonPRO
Start date: September 2015
Phase: N/A
Study type: Interventional

The objective of the research is to determine whether the MyotonPRO has a valid and reliable application in facial, head and neck surgery. In addition, the study aims to compare this new technology with current electromyography.

NCT ID: NCT02488915 Completed - Stroke Clinical Trials

Analysis of Revascularization in Ischemic Stroke With EmboTrap

ARISEII
Start date: November 2015
Phase: N/A
Study type: Interventional

The study objective is to examine the recanalization efficacy of the EmboTrap device and its associated performance characteristics and to record associated clinical outcomes in a manner that facilitates relevant comparison of outputs with that of devices approved in the U.S. for clearing Large Vessel Occlusions.

NCT ID: NCT02488759 Completed - Clinical trials for Various Advanced Cancer

An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors

CheckMate358
Start date: October 13, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study to investigate the safety and effectiveness of nivolumab, and nivolumab combination therapy, to treat patients who have virus-associated tumors. Certain viruses have been known to play a role in tumor formation and growth. This study will investigate the effects of the study drugs, in patients who have the following types of tumors: - Anal canal cancer-No longer enrolling this tumor type - Cervical cancer - Epstein Barr Virus (EBV) positive gastric cancer-No longer enrolling this tumor type - Merkel Cell Cancer - Penile cancer-No longer enrolling this tumor type - Vaginal and vulvar cancer-No longer enrolling this tumor type - Nasopharyngeal Cancer - No longer enrolling this tumor type - Head and Neck Cancer - No longer enrolling this tumor type

NCT ID: NCT02487433 Completed - Healthy Clinical Trials

A Study To Evaluate The Effect Of Food On The Behavior of Tofacitinib Modified Release 22 Milligram Tablets In Healthy Volunteers

Start date: June 2015
Phase: Phase 1
Study type: Interventional

This study will evaluate the drug behavior and safety of a single dose of the 22 milligram tofacitinib (CP-690,550) modified-release formulation in 18 healthy volunteers when taken after eating a high fat meal (the effect of food). This will be compared to the drug behavior and safety of a single dose of the 22 milligram tofacitinib (CP-690,550) modified-release formulation when taken after a 10 hour fast.